Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

NCT02327078 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02327078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02327078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
November 26, 2014
Completion date
June 16, 2020
Enrollment
307 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies, colorectal cancer (crc), glioblastoma, head and neck cancer, lung cancer, lymphoma, melanoma, ovarian cancer